ResMed Inc: 4Q mixed - sales solid but ‘altruism’ sees softer GPM

About the author:

Author name:

By Dr Derek Jellinek

Job title:

Senior Analyst

Date posted:

07 August 2023, 7:00 AM

Sectors Covered:

Healthcare

• ResMed Inc's (ASX:RMD) 4Q was mixed, as strong sales across all product lines failed to translate into operating leverage.
• Unconstrained supply and Philips continued market absence supported device growth, while masks benefited from resupply programs and new patient setups.
• While softer GPM disappointed, a bit of altruism appears to be at play, as demand fulfillment, despite unfavourable product mix and higher inventory component costs, trumped short-term profit growth. However, we believe an expanding installed base and franchised customers should not be frowned upon by the market, with margins likely to improve through FY24 on abating headwinds.
• We adjust FY23-25 forecasts modestly, with our DCF/SOTP based target price decreasing to (login to view). Add rating maintained.

Find out more

If you would like more information, please contact your adviser or nearest Morgans office.

Disclaimer: The information contained in this report is provided to you by Morgans Financial Limited as general advice only, and is made without consideration of an individual's relevant personal circumstances. Morgans Financial Limited ABN 49 010 669 726, its related bodies corporate, directors and officers, employees, authorised representatives and agents (“Morgans”) do not accept any liability for any loss or damage arising from or in connection with any action taken or not taken on the basis of information contained in this report, or for any errors or omissions contained within. It is recommended that any persons who wish to act upon this report consult with their Morgans investment adviser before doing so.